Clinical trials: Delayed Diagnosis Pulmonary Hypertension, open to volunteers
Obesity, Interstitial Lung Disease
Feasibility of Semaglutide in Advanced Lung Disease
The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question[s] it aims to answer are: 1.
- Conditions
- Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary
- Trial name
- NCT05746039
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
PulmonAry hyperteNsion DiagnOsis: a National cohoRt reseArch
Understanding Delays in the Diagnosis of Pulmonary Arterial Hypertension and Rare Diseases in Brazil: A Multicenter Observational Study --- Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension
- Trial name
- PANDORA (NCT06998329)
- Testing
- There will be no intervention
- Where
- Brazil
- Volunteers
- 139 people
- Sponsor
- University of Sao Paulo General Hospital
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.
Delayed Diagnosis Pulmonary Hypertension
Diagnostic Delay in PHTN
Pulmonary hypertension (PH) is a progressive cardiopulmonary condition that may remain undiagnosed for a prolonged period because its initial symptoms are often nonspecific.
- Trial name
- NCT07810881
- Volunteers
- 80 people
- Sponsor
- Assiut University